Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant, ultrapure, TLR4 tested
-
Catalog number
AV-7016-5
-
Price
Please ask
-
Size
5 mg
-
-
Stock availability
Available
-
Category
Adjuvant/ODNs
-
Antibody type
N/A
-
Antibody host
N/A
-
Antibody conjugate
N/A
-
Technical datasheet
Contact Gentaur to request the datasheet or ask our specialists for more information.
-
Notes
The Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant, ultrapure, TLR4 tested is manufactured for Research Use Only or for diagnostics purposes.
-
-
Gene
Bacterial pathogen lipopolysaccharides (LPS) are the major outer surface membrane components present in almost all Gram-negative bacteria and act as extremely strong stimulators of innate or natural immunity in diverse eukaryotic species ranging from insects to humans. LPS consist of a poly- or oligosaccharide region that is anchored in the outer bacterial membrane by a specific carbohydrate lipid moiety termed lipid A. The lipid A component is the primary immunostimulatory center of LPS. With respect to immunoactivation in mammalian systems, the classical group of strongly agonistic (highly endotoxin) forms of LPS has been shown to be comprised of a rather similar set of lipid A types. In addition, several natural or derivative lipid A structures have been identified that display comparatively low or even no immunostimulation for a given mammalian species. Some members of the latter more heterogeneous group are capable of antagonizing the effects of strongly stimulatory LPS/lipid A forms. Agonistic forms of LPS or lipid A trigger numerous physiological immunostimulatory effects in mammalian organisms, but--in higher doses--can also lead to pathological reactions such as the induction of septic shock. Cells of the myeloid lineage have been shown to be the primary cellular sensors for LPS in the mammalian immune system. During the past decade, enormous progress has been obtained in the elucidation of the central LPS/lipid A recognition and signaling system in mammalian phagocytes. According to the current model, the specific cellular recognition of agonistic LPS/lipid A is initialized by the combined extracellular actions of LPS binding protein (LBP), the membrane-bound or soluble forms of CD14 and the newly identified Toll-like receptor 4 (TLR4)*MD-2 complex, leading to the rapid activation of an intracellular signaling network that is highly homologous to the signaling systems of IL-1 and IL-18. The elucidation of structure-activity correlations in LPS and lipid A has not only contributed to a molecular understanding of both immunostimulatory and toxic septic processes, but has also re-animated the development of new pharmacological and immuno-stimulatory strategies for the prevention and therapy of infectious and malignant diseases.
-
Gene target
-
Gene symbol
IRF6, TLR4
-
Short name
Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant, ultrapure, TLR4 tested
-
Host
Escherichia coli
-
Species
Custom Service
-
Alternative name
Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) immunization adjuvant, ultrapure, toll-like receptor 4 tested
-
Alternative technique
escherichia
-
Alternative to gene target
toll-like receptor 4, ARMD10 and CD284 and TLR-4 and TOLL, TLR4 and IDBG-82738 and ENSG00000136869 and 7099, protein binding, Cell surfaces, Tlr4 and IDBG-156729 and ENSMUSG00000039005 and 21898, TLR4 and IDBG-638758 and ENSBTAG00000006240 and 281536
-
Gene info
Gene info
-
Identity
-
Gene
-
Long gene name
toll like receptor 4
-
Synonyms gene name
-
Synonyms
-
GenBank acession
-
Locus
-
Discovery year
1998-06-25
-
Entrez gene record
-
Pubmed identfication
-
RefSeq identity
-
Classification
- Toll like receptors
- CD molecules
-
VEGA ID
-
Locus Specific Databases
Product images
Similar products